Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd consolidation in PET-positive multiple myeloma after standard first-line therapy
2017-000586-72Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Oslo University Hospital. Primary endpoint: PET-CT conversion after KRd consolidation. Started Aug 2017; status: active.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-000586-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000586-72.